Lindynette 20 #21x3

Lindynette instruction

Reed more about Lindynette and buy it here

Lindynette 20 is a combined medicinal product in the form of tablets, which has a contraceptive effect and is used for regular planned contraception.
The structure of Lindynette includes 2 components, the combination of which causes a reliable contraceptive effect - ethinyl estradiol and gestodene. Possessing an estrogen-progestogen effect, the drug causes oppression of the pituitary secretion of gonadotropins. The mechanism of action is that its components interfere with the maturation of the egg to prevent its fertilization.
Estrogenic action is caused by a highly effective component - ethinyl estradiol, which is a hormonal agent of the estrogenic series produced by the ovaries and adrenals. Together with progesterone, it is able to regulate the menstrual cycle, cause division and multiplication of endometrial cells, stimulate the development of the uterus and secondary signs of the female body when they are deficient, soften and eliminate the consequences of dysfunction of the sexual glands. Also, ethinyl estradiol causes a decrease in cholesterol in the blood.
The gestagenic component is represented by Gestodene, a synthetic progestin similar in structure to levonorgestrel, which is superior in strength and selectivity to both progesterone and levonorgestrel. It causes oppression of the synthesis of follitropin and luteotropin by the pituitary gland and blocks ovulation.
In addition to the above effects, which lead to the lack of fertilization, contraception is supported by a decrease in the susceptibility of the endometrium of the uterus to the blastocyst, as well as an increase in the viscosity of mucus in the cervix, which makes it difficult to pass through it spermatozoa. With regular use, Lindynette has not only a contraceptive effect, but also is used to normalize the menstrual cycle and reduces the likelihood of developing reproductive system diseases, including neoplasms.
Lindynette is a preparation of the prescription group and can be used only after careful collection of anamnesis and subsequent appointment of a specialist.

Form of issue and composition

The dosage form is presented in tablets with a dosage of ethinylestradiol 0.02 mg and Gestodene 0.075 mg. It is produced in packages:
    №21;
    №21 * 3.
The production belongs to the company Gedeon Richter, Hungary.

Indications for use

    contraception.

Contraindications

Contraindications are the development or presence in the history of the following manifestations:
    Hypersensitivity to a combination of hormones or its individual components;
    a pronounced tendency or presence of factors predisposing to the onset of thrombosis;
    unstable hypertension;
    precursors of thrombosis, manifested by ischemia;
    migraine, accompanied by focal neurological symptoms;
    thrombotic or thromboembolic lesions of veins and arteries;
    thromboembolic congestion of the veins of relatives;
    surgical intervention with prolonged immobility;
    diabetic angiopathy against diabetes mellitus;
    inflammation of the pancreas with marked increase in the level of triglycerides in the blood;
    dyslipidemic syndrome;
    inflammation and other severe liver damage;
    jaundice of the skin as a result of the use of steroid preparations;
    cholelithiasis;
    some forms of pigmentary hepatosis;
    hepatic neoplasms;
    severe itching, answering;
    hormone-dependent neoplastic tumors of the reproductive system and mammary glands;
    bleeding from the vagina;
    smoking after 35 years;
    pregnancy;
    lactation.
The use in these situations is allowed only if care is taken:
    conditions in which the possibility of thrombotic / thromboembolic lesions of veins or arteries, including smoking, age over 35, the presence of such conditions in the family, increases;
    hemolytic uremic syndrome;
    Quincke's edema, transmitted by heredity;
    liver disease;
    diseases that appeared or worsened during pregnancy or with the use of hormonal drugs earlier, such as porphyria, herpes, rheumatic chorea, chloasma;
    obesity;
    dyslipoproteinemic syndrome;
    hypertonic disease;
    migraine;
    convulsive disorders;
    pathology of the heart valves;
    atrial fibrillation;
    prolonged immobility;
    extensive surgical intervention;
    severe trauma;
    varicose veins and thrombophlebitis of superficial veins;
    period after childbirth;
    severe depressive syndrome;
    changes in blood biochemistry;
    diabetes mellitus without vascular disease;
    Libmann-Sachs disease;
    granulomatous enteritis;
    ulcerous inflammation of the large intestine;
    sickle-cell anemia;
    increased triglyceride levels in the blood;
    acute and chronic hepatic diseases.

Dosing and Administration

Tablets are taken orally, regardless of food, 1 tablet a day. After 3 weeks, take a break for 1 week, after which I start again. In the interval between taking hormones, menstrual bleeding occurs.
Admission of hormones should start from the 1st to the 5th day of the menstrual cycle, if they are taken for the first time.
In case of changing another combined contraceptive to Lindynette: the first tablet of Lindynette is taken the next day after the last hormone tablet of the previous preparation, on the first day of menstruation.
In case of changing progestin drugs to Lindynette: taking Lindynette after progestogen tablets is possible on any day of the menstrual cycle, after the implant - on the day after its removal, after injections - on the eve of the last injection.
In the first week of using Lindynette 20, ancillary measures of contraception should be used.

Side effects

1. Cancellation is necessary for the development of the following violations:
    hypertension;
    hemolytic-uremic syndrome;
    porphyria;
    loss of hearing in the background otpesgioza.
2. Rare violations: thromboembolic lesions of veins and arteries of the circulatory system, brain, lower extremities, lungs, exacerbation of Liebman-Sachs disease;
3. Very rare disorders: thromboembolic lesions of veins or arteries of the liver, mesenteria, kidney, retina, chorea;
4. Frequent violations:
    reproductive system: non-cyclic vaginal hemorrhages or discharge, absence of menstruation when Lindint is withdrawn, changes in the state of the vaginal mucus, vaginal inflammation, changes in libido;
    chest glands: discomfort, pain, enlargement, galactorrhea;
    digestive disorders: nausea, vomiting, diarrhea, epigastric pain, granulomatous enteritis, ulcerative colon inflammation, hepatitis, adenomatous liver damage, itching or icterus against bile stasis, cholelithiasis;
    skin: erythema, rashes, hyperpigmentation, alopecia;
    neurological disorders: headache, migraine, emotional lability, depression;
    changes in metabolism: fluid retention, weight gain, hypertriglyceridemia, hyperglycemia, decreased tolerance to carbohydrate compounds;
    analyzers: worsening of hearing, discomfort in the eyes when using contact lenses;
    other: manifestations of hypersensitivity.

special instructions

    during pregnancy and lactation this drug is contraindicated;
    before his appointment, it is necessary to collect all the anamnestic data of the patient and his immediate family, and conduct a medical and gynecological examination every six months to identify risk factors or contraindications;
    the study proved that Lindynette is a highly effective oral contraceptive, as the number of pregnancies that occurred when taking the drug in 100 women for 1 year was about 0.05;
    since the contraceptive effect is fully developed by the 14th day of use, then during its gradual development it is desirable to use auxiliary non-hormonal contraceptive methods;
    the appointment of a contraceptive is individual in each case. Before it is necessary to evaluate all the pros and cons of using the drug and discuss them with the patient, who, guided by the information received, should make a choice of method of contraception. Careful monitoring of the woman's condition is necessary;
    in case of increased symptoms of one of these diseases, hormonal withdrawal requires the abolition of the contraceptive and the use of nonhormonal contraceptives: hemostasis disorders that cause the development of circulatory or renal insufficiency, convulsive disorders, migraine, an increased likelihood of a hormone-dependent neoplasm or gynecological disease, diabetes mellitus without complications of a vascular nature, pronounced depressive syndrome, anemia, laboratory abnormalities indicators;
    it must be borne in mind that the existence of a link between the use of oral hormones and the development of thrombosis and embolism of various organs and systems has been scientifically proven;
    Increased risk of thromboembolic injury occurs with age, with smoking, with a family propensity to thromboembolism, with obesity, with dyslipoproteinemic syndrome, with hypertension, with heart valve pathologies, atrial fibrillation, diabetes mellitus with vascular damage, with prolonged immobility due to operative interventions;
    the likelihood of thromboembolism increases in women in the postpartum period;
    diabetes mellitus, Liebman-Sachs disease, hemolytic uremic syndrome, granulomatous enteritis, ulcerative ulcerative inflammation of the large intestine, sickle cell anemia increase the likelihood of venous thromboembolism;
    some biochemical deviations may trigger a risk of thromboembolism of the arteries and veins, but the treatment of these disorders reduces the risk of thromboembolism. Symptoms of thromboembolic injury: chest pain radiating to the left arm, shortness of breath, severe headache, especially accompanied by deterioration or loss of vision, speech disorder, dizziness, cardiovascular insufficiency, epileptic seizure, unilateral weakness or numbness of the body, pain in the gastrocnemius muscle, disorders motor functions, acute abdomen;
    there are data on the increased incidence of cervical cancer with prolonged use of the contraceptive. However, the results of research are contradictory, since there are many different factors affecting the development of cancer;
    At appointment it is necessary to consider, that use of oral contraceptive means is one of factors of development of a cancer of mammary glands about what it is necessary to inform the patient;
    in the case of the appearance of pain in the abdomen and their diagnosis, it must be taken into account that there is some amount of data on the occurrence of a benign or malignant neoplasm with prolonged intake of oral contraceptives, so that they can be caused by hepatomegaly or bleeding into the abdominal cavity;
    the drug does not protect against infection with the virus of immunodeficiency and other sexually transmitted diseases;
    a decrease in efficacy may occur with admission, vomiting, diarrhea, the use of drugs that reduce the effect of the contraceptive;
    when taking other medications that reduce the effectiveness of the contraceptive, the use of ancillary contraception is necessary;
    after a while, there may be a decrease in the effectiveness of the drug and the appearance of various types of bleeding, in which the use of hormones continues until the end of the next package. If after this there is no menstruation or bloating and bleeding does not stop, you must stop taking Lindynette and resume only after the exclusion of pregnancy;
    Chloasma usually occurs in women who have it during pregnancy. With a tendency to the emergence of chloasma, it is necessary to avoid solar or ultraviolet influences at the time of admission;
    estrogens can affect internal organs, for example, the liver, kidneys, adrenals, thyroid gland and others, and change the indicators of laboratory data;
    application after the transferred virus defeat of a liver is possible only in half a year. The contraceptive effect may decrease with intestinal disorders and vomiting, as a result of which it is necessary to use auxiliary methods of contraception. Smoking when taking medication increases the risk of vascular disease, especially after 35 years;
    There is no data on the safety of reception when driving a car or doing other work that requires a reaction speed.

Drug Interactions

    rifampicin causes a decrease in the contraceptive effect, and also increases the likelihood of breakthrough bleeding and menstrual irregularities;
    a decrease in the effect is also observed when taking carbamazepine, primidone, derivatives of barbituric acid, phenylbutazone, phenytoin. there is a likelihood of the same effect when treated with griseofulvin, ampicillin, or tetracycline drugs. Therefore, for the period of therapy with these drugs and 1 week after the end of treatment, it is recommended to use an auxiliary method of contraception (condom, spermicide gel);
    decrease in the absorption of the contraceptive occurs with the development of diarrhea;
    drugs that are able to shorten the period of the drug in the large intestine, reduce the level of hormones in the blood;
    the bioavailability of ethinyl estradiol is increased, and the metabolism is slowed by the use of agents that undergo sulphation in the intestinal wall: barbituric acid derivatives, phenylbutazone, oxcarbazepine, griseofulvin, some anticonvulsant and anti-tuberculosis drugs, and other substances inducing hepatic enzyme activity lower the level of ethinylestradiol in the blood;
    itraconazole, fluconazole and other drugs that block hepatic enzymes increase the level of ethinyl estradiol in the blood;
    ampicillin and tetracycline antibiotics interfere with intrahepatic estrogen circulation and cause a decrease in the level of ethinyl estradiol in the blood;
    ethinyl estradiol blocks hepatic enzymes or speeds up conjugation and affects the metabolism of certain drugs such as cyclosporine, theophylline, and leads to an increase or decrease in their level in the blood;
    since St. John's wort and preparations based on it are active inducers of hepatic enzymes, the use of this group of agents is undesirable. It should be noted that induction can be observed for 2 more weeks after the withdrawal of St. John's wort;
    ritonavir lowers the AUC value of ethinylestradiol. As a result, at the time of taking ritonavir, a drug with a higher ethinylestradiol content or using barrier methods is recommended;
    the agent can help to reduce tolerance to carbohydrates and increase the need for insulin or tableted hypoglycemic drugs, which may necessitate dose adjustment.

Terms and conditions of storage

Lindynette is suitable for use within 3 years from the date of manufacture. Use after the end of this period is prohibited. Proper storage of contraceptive medication:
     a place protected from the rays;
     out of children's access;
     temperature up to 25 degrees.